Results 11 to 20 of about 564,053 (333)

Platelet factor 4 polyanion immune complexes: heparin induced thrombocytopenia and vaccine-induced immune thrombotic thrombocytopenia

open access: yesThrombosis Journal, 2021
Background This is a review article on heparin-induced thrombocytopenia, an adverse effect of heparin therapy, and vaccine-induced immune thrombotic thrombocytopenia, occurring in some patients administered certain coronavirus vaccines.
Payel Datta   +3 more
doaj   +1 more source

Influence of different levels of heparin and antithrombin Ⅲ on human coagulation factor Ⅸ activity

open access: yesZhongguo shuxue zazhi, 2022
Objective To study the effect of different concentrations of heparin, ATⅢ or a mixture of heparin and antithrombin Ⅲ (ATⅢ) (1∶1)on the activity of human coagulation factor Ⅸ (FⅨ).
Changyong JIAN   +5 more
doaj   +1 more source

Quantitative Analysis of Impurities in Unfractionated Heparin of Bovine Origin

open access: yesFrontiers in Medicine, 2020
The USP heparin sodium monograph lists impurities with specifications developed for porcine derived products. Most of these impurities are of biological origin and are present in porcine intestinal mucosa, the tissue source used in the production of ...
Wesley E. Workman, Kevin L. Carrick
doaj   +1 more source

Heparin-induced thrombocytopenia occurring early after living donor liver transplantation: a case report

open access: yesEmergency and Critical Care Medicine, 2023
. Background. Thrombocytopenia commonly occurs early after liver transplantation. Heparin, usually administered as anticoagulant therapy for thrombosis, a common complication after liver transplantation, may cause heparin-induced thrombocytopenia ...
Naoya Iwasaki   +13 more
doaj   +1 more source

Blended Heparin: A new Perspective to Guarantee the Supply of a Life-Saving Drug?

open access: yesClinical and Applied Thrombosis/Hemostasis, 2023
The risk of heparin shortage opens up the possibility of diversifying the sources of heparin by introducing products of other animal/organ origins. In addition to bovine heparin, already used in the past in the United States and Europe, ovine heparin can
Marco Guerrini MS
doaj   +1 more source

Heparin-induced thrombocytopenia: a rare presentation with skin necrosis

open access: yesDermatology Reports, 2023
Heparin-induced thrombocytopenia is the most clinically relevant non-haemorrhagic complication of heparin and is characterised by the presence of anti-PF4/heparin-IgG antibodies.
Filipa David   +3 more
doaj   +1 more source

pH-Sensitive Chitosan–Heparin Nanoparticles for Effective Delivery of Genetic Drugs into Epithelial Cells [PDF]

open access: yes, 2019
Chitosan has been extensively studied as a genetic drug delivery platform. However, its efficiency is limited by the strength of DNA and RNA binding.
Korzhikov-Vlakh, Viktor   +7 more
core   +1 more source

An Ovarian Cancer Patient Presenting Heparin - Induced Thrombocytopenia after use of Low - Molecular - Weight Heparin: A Case Report of Rare Condition

open access: yesGynecology Obstetrics & Reproductive Medicine, 2019
Heparin-induced thrombocytopenia is a rare and life-threatening condition of exposure to heparin. A case of heparin-induced thrombocytopenia due to the low molecular weight heparin was presented.
Yasin Durmuş   +8 more
doaj   +1 more source

Rivaroxaban Treatment for Heparin-Induced Thrombocytopenia: A Case Report and a Review of the Current Experience

open access: yesCase Reports in Hematology, 2020
Heparin-induced thrombocytopenia is a life-threatening complication of exposure to heparin. Heparin-induced thrombocytopenia results from an autoantibody directed against platelet factor 4 in complex with heparin.
Mohamed Aon, Omar Al-Shammari
doaj   +1 more source

Home - About - Disclaimer - Privacy